IL6 and disease of the tendon: IHC staining revealed that NGR1 exhibited a dose-dependent therapeutic effect on tendinopathy, including reducing the expression of the inflammatory cytokine IL-6, downregulating Col3 and MMP3 expression, and upregulating Col1 expression at 5 weeks (Figure 3).